Page last updated: 2024-11-05

trihexyphenidyl and Pantothenate Kinase-Associated Neurodegeneration

trihexyphenidyl has been researched along with Pantothenate Kinase-Associated Neurodegeneration in 1 studies

Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.

Pantothenate Kinase-Associated Neurodegeneration: A rare autosomal recessive degenerative disorder which usually presents in late childhood or adolescence. Clinical manifestations include progressive MUSCLE SPASTICITY; hyperreflexia; MUSCLE RIGIDITY; DYSTONIA; DYSARTHRIA; and intellectual deterioration which progresses to severe dementia over several years. (From Adams et al., Principles of Neurology, 6th ed, p972; Davis & Robertson, Textbook of Neuropathology, 2nd ed, pp972-929)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kuo, SH1
Greene, P1

Other Studies

1 other study available for trihexyphenidyl and Pantothenate Kinase-Associated Neurodegeneration

ArticleYear
Clinical reasoning: a 16-year-old boy with freezing of gait.
    Neurology, 2010, Aug-10, Volume: 75, Issue:6

    Topics: Adolescent; Gait Disorders, Neurologic; Humans; Male; Pantothenate Kinase-Associated Neurodegenerati

2010